Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $10.50 USD
Change Today +0.06 / 0.57%
Volume 120.6K
MDXG On Other Exchanges
Symbol
Exchange
NASDAQ CM
Berlin
As of 11:29 AM 03/27/15 All times are local (Market data is delayed by at least 15 minutes).

mimedx group inc (MDXG) Snapshot

Open
$10.45
Previous Close
$10.44
Day High
$10.84
Day Low
$10.38
52 Week High
12/22/14 - $11.97
52 Week Low
05/7/14 - $4.88
Market Cap
1.1B
Average Volume 10 Days
953.8K
EPS TTM
$0.05
Shares Outstanding
108.1M
EX-Date
--
P/E TM
210.0x
Dividend
--
Dividend Yield
--
Current Stock Chart for MIMEDX GROUP INC (MDXG)

Related News

No related news articles were found.

mimedx group inc (MDXG) Related Businessweek News

No Related Businessweek News Found

mimedx group inc (MDXG) Details

MiMedx Group, Inc. designs, manufactures, and markets products and tissue processing services in the United States. The company’s products include patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane. Its biomaterial platform technologies comprise AmnioFix and EpiFix, which are tissue technologies processed from human amniotic membrane that is derived from donated placentas. Through the company’s donor program, mothers delivering full-term Caesarean section births can elect in advance of delivery to donate the placenta in lieu of having it discarded as medical waste. It processes the human amniotic membrane utilizing its proprietary PURION process to produce allograft, an easy to use and effective implant. The company also provides CollaFix, a medical device technology platform, that creates fibers from soluble collagen and a specialized cross-linking process; and HydroFix products, which are based on licenses to patents and patent application rights to a PVA- based hydrogel, a water-based biomaterial. It supplies amniotic tissue approximately 350,000 allografts on OEM basis for application in the wound care, surgical, sports medicine, ophthalmic, and dental sectors of healthcare through direct sales force, independent sales representatives, and distributors, as well as through private label or OEM relationships. The company is headquartered in Marietta, Georgia.

386 Employees
Last Reported Date: 03/13/15

mimedx group inc (MDXG) Top Compensated Officers

Chairman and Chief Executive Officer
Total Annual Compensation: $465.2K
President, Chief Operating Officer and Direct...
Total Annual Compensation: $385.6K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $268.3K
Advisory Counsel
Total Annual Compensation: $240.0K
Compensation as of Fiscal Year 2013.

mimedx group inc (MDXG) Key Developments

MiMedx Group, Inc. Presents at Canaccord Genuity 10th Annual Musculoskeletal Conference, Mar-24-2015 10:00 AM

MiMedx Group, Inc. Presents at Canaccord Genuity 10th Annual Musculoskeletal Conference, Mar-24-2015 10:00 AM. Venue: MGM Grand Hotel, Las Vegas, Nevada, United States. Speakers: Michael J. Senken, Chief Financial Officer, Principal Accounting Officer and Vice President, Parker H. Petit, Chairman and Chief Executive Officer, William Charles Taylor, President, Chief Operating Officer and Director.

MiMedx Group, Inc. Announces Executive Changes

On February 25, 2015, Roberta McCaw announced her official retirement from her role as General Counsel and Secretary of MiMedx Group, Inc. effective February 28, 2015. Although her employment with the company will terminate on March 31, 2015, Ms. McCaw will continue to serve as Advisory Counsel under a three year consulting arrangement. Ms. McCaw originally planned on retirement in mid-2013, but agreed to continue her position until a successor was hired and trained. Alexandra O. Haden, Assistant General Counsel, has been appointed to succeed Ms. McCaw as the company's General Counsel and Secretary pursuant to the succession plan referenced above. Ms. Haden was hired in June 2013 with the expectation that she would succeed Ms. McCaw upon her eventual retirement.

MiMedx Group, Inc. Reports Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014; Reiterates Earnings Guidance for the First Quarter and Full Year 2015

MiMedx Group, Inc. reported consolidated earnings results for the fourth quarter and full year ended December 31, 2014. For the quarter, the company reported revenue of $39.6 million, a $21.6 million or 120% increase over 2013 fourth quarter revenue of $18.0 million, and sequentially, a $6.1 million or 18% increase over third quarter of 2014 revenue. Adjusted EBITDA was $8.5 million, a $7.2 million or 542% improvement, as compared to Adjusted EBITDA of $1.3 million for the fourth quarter of 2013. Net Income was $3.8 million, or $0.03 per diluted common share, a $5.3 million improvement, as compared to the Net Loss of $1.4 million, or $0.01 per diluted common share, in the 2014 fourth quarter. Operating profit was $4.7 million is 12% of revenue. For the year, the company reported net sales of $118.223 million against $59.181 million a year ago. Operating income was $7.100 million against operating loss of $2.639 million a year ago. Income before income tax provision was $7.052 million against loss before income tax provision of $4.012 million a year ago. Net income was $6.220 million or $0.05 per diluted share against net loss of $4.112 million or $0.04 per diluted share a year ago. Net cash inflows from operating activities were $16.802 million against net cash outflows from operating activities of $0.284 million a year ago. Purchases of equipment were $2.558 million against $2.337 million a year ago. Adjusted EBITDA was $20.678 million against $5.467 million a year ago. The company reiterated its previously communicated guidance for full year 2015 and the first quarter of 2015. For the first quarter, the company expects revenue to be the range of $40 million to $41 million; and operating profit in excess of 10%. For the full year, the company expects revenue to be in the range of $175 million to $190 million; and operating profit margin in excess of 15%.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MDXG:US $10.52 USD +0.08

MDXG Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Osiris Therapeutics Inc $17.80 USD +0.36
Smith & Nephew PLC 1,142 GBp -6.00
View Industry Companies
 

Industry Analysis

MDXG

Industry Average

Valuation MDXG Industry Range
Price/Earnings 100.0x
Price/Sales 9.5x
Price/Book 12.7x
Price/Cash Flow 157.0x
TEV/Sales 9.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MIMEDX GROUP INC, please visit www.mimedx.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.